Re-Vana Therapeutics has entered a partnership and licence agreement with Boehringer Ingelheim for the development of eye therapies.

Boehringer Ingelheim partners with Re-Vana Therapeutics to innovate long-acting eye disease treatments, enhancing patient care and compliance.

Queens University spin-out Re-Vana Therapeutics has agreed a $1bn deal with biopharma giant Boehringer Ingelheim.

Boehringer Ingelheim and Re-Vana Therapeutics, a U.S. and UK based developer of ocular therapeutics and drug delivery ...

By registering you consent to the collection and use of your information to provide the products and services you have requested from us and as described in our privacy policy and terms and conditions ...

Ophthalmology Times connects eye care professionals with surgery, imaging, gene therapy, & diagnostic advances to enhance ...

The German giant is looking to develop new drugs for undisclosed eye diseases using Re-Vana’s extended-release injectable ...

People in 15 regions across the U.S. will soon benefit from the American Heart Association's Cardiovascular-Kidney-Metabolic ...

Re-Vana Therapeutics develops products to improve the delivery of drugs for chronic eye diseases, increasing the quality of ...

Boehringer Ingelheim is continuing to explore its newfound enthusiasm for eye health, penning a $1 billion biobucks pact with ...

Queen’s University Belfast spin-out company Re-Vana Therapeutics has signed a landmark collaboration deal with German ...